Masked hypertension in children and adolescents Empar Lurbe Invited Commentary 10 October 2008 Pages: 165 - 166
Prevention of atrial fibrillation in hypertension Tonje A. AksnesArnljot FlaaSverre E. Kjeldsen OriginalPaper 10 October 2008 Pages: 175 - 181
Hypertension and hepatic steatosis Matthew J. BrookesTariq H. IqbalBrian T. Cooper OriginalPaper 10 October 2008 Pages: 182 - 187
The angiotensin II type 2 receptor: What is its clinical significance? Ivonne Hernandez SchulmanLeopoldo Raij OriginalPaper 10 October 2008 Pages: 188 - 193
Now that we have a direct renin inhibitor, what should we do with it? Alice Stanton OriginalPaper 10 October 2008 Pages: 194 - 200
Using health information technology to improve hypertension management Mary K. Goldstein OriginalPaper 10 October 2008 Pages: 201 - 207
Mineralocorticoid antagonism and cardiac hypertrophy Kohzo Nagata OriginalPaper 10 October 2008 Pages: 216 - 221
Obesity, sleep apnea, aldosterone, and hypertension Theodore L. Goodfriend OriginalPaper 10 October 2008 Pages: 222 - 226
Angiotensin-(1-7) as an antihypertensive, antifibrotic target Michael J. KatovichJustin L. GrobeMohan K. Raizada OriginalPaper 10 October 2008 Pages: 227 - 232
Neurohormonal regulation of the sympathetic nervous system: New insights into central mechanisms of action Scott H. CarlsonJ. Michael Wyss OriginalPaper 10 October 2008 Pages: 233 - 240
Sympathetic neural mechanisms in human hypertension Ronald G. VictorMoiz M. Shafiq OriginalPaper 10 October 2008 Pages: 241 - 247